Dhatt Jovan, Houser Karis, Szymanski Kathryn A, Halderman Kelly, Kuwabara Michael
Midwestern University - Arizona College of Osteopathic Medicine, 19555 59 Ave, Glendale, AZ 85308, USA.
Phoenix Children's Hospital, Department of Radiology, 1919 E Thomas Rd, Phoenix, AZ 85016, USA.
Radiol Case Rep. 2024 Dec 12;20(3):1323-1327. doi: 10.1016/j.radcr.2024.11.023. eCollection 2025 Mar.
Wyburn-Mason disease (WMD) is a rare congenital phakomatosis known for its complex arteriovenous malformations (AVMs) predominantly affecting the brain and ocular structures. We present the case of a 19-year-old female with an unruptured Spetzler-Martin grade 5 left thalamic AVM, who initially exhibited progressive visual impairment and migraines. Following diagnosis, she was treated with trametinib, a MEK inhibitor; however, nine months later, she developed acute complications, including left monocular blindness and right hemisensory loss. Imaging revealed narrowing of the left internal carotid artery and ischemia, leading to the discontinuation of trametinib. Her condition stabilized with gabapentin and supportive therapies. This case emphasizes the potential therapeutic role and risks of MEK inhibitors in managing high-grade AVMs in WMD and highlights the need for individualized management and careful monitoring in such cases.
怀伯恩 - 梅森病(WMD)是一种罕见的先天性错构瘤病,以其主要影响脑和眼部结构的复杂动静脉畸形(AVM)而闻名。我们报告了一例19岁女性,患有未破裂的斯佩茨勒 - 马丁5级左丘脑动静脉畸形,最初表现为进行性视力损害和偏头痛。诊断后,她接受了MEK抑制剂曲美替尼治疗;然而,九个月后,她出现了急性并发症,包括左单眼失明和右半身感觉丧失。影像学检查显示左颈内动脉狭窄和缺血,导致曲美替尼停药。她的病情通过加巴喷丁和支持性治疗得以稳定。该病例强调了MEK抑制剂在治疗WMD中高级别AVM方面的潜在治疗作用和风险,并突出了在此类病例中进行个体化管理和仔细监测的必要性。